Relationship between first radioactive iodine administration time and initial response to treatment in patients with papillary thyroid carcinoma

Document Type : Original Article


1 Nuclear Medicine and Molecular Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Biostatistics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran


Introduction: The initial post-surgical radioactive iodine (RAI) therapy for patients with papillary thyroid cancer (PTC) is postponed due to increased demand as well as the limited number of centers to provide RAI therapy. Hence, our aim was to investigate the role of first RAI administration time following thyroidectomy on the number of incomplete response (IR) during the initial follow up, while considering other prognostic factors.
Methods: Two hundred and thirty-five PTC patients who were admitted to our department for RAI therapy were included in this study. They were allocated into two groups with <3 months (early group) and ≥ 3 months (delayed group) time interval after the first RAI therapy, and the total thyroidectomy. Then, based on the response to RAI therapy, patients were categorized as excellent, biochemical incomplete, structural incomplete, or indeterminate responses (ER, BIR, SIR or IDR, respectively).
Results: With respect to age, gender, pathologic variables, RAI dose rate and IR (BIR+SIR) rate, significant differences were found between the two groups. The findings identified that early RAI failed to affect the rate of IR (univariate analysis: HR=1.09, 95%CI: 0.69-1.74, P=0.71; Cox model: HR=0.81, 95%CI: 0.46-1.44, P=0.47). However, Cox multivariate analysis found lymph node status and thyroglobulin level (Lymph node status: HR=2.88, 95%CI: 1.07-7.78, P=0 .04) as independent risk factors for IR during the initial follow up.
Conclusion: Therefore, timing of the first post-surgery RAI therapy is not a significant prognosticator of the initial response of patients to therapy.


Main Subjects

  1. Tsirona S, Vlassopoulou V, Tzanela M, Rondogianni P, Ioannidis G, Vassilopoulos C, Botoula E, Trivizas P, Datseris I, Tsagarakis S. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low‐risk well‐differentiated thyroid cancer. Clin Endocrinol (Oxf). 2014;80(3):459-63.
  2. Suman P, Wang C-H, Moo-Young TA, Prinz RA, Winchester DJ. Timing of adjuvant radioactive iodine therapy does not affect overall survival in low-and intermediate-risk papillary thyroid carcinoma. Am Surg. 2016;82(9):807-14.
  3. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22.
  4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE,  Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
  5. Haghighatafshar M, Banani A, Zeinali-Rafsanjani B, Etemadi Z, Ghaedian T. Impact of the amount of liquid intake on the dose rate of patients treated with radioiodine. Indian J Nucl Med. Jan-Mar 2018;33(1):10-13.
  6. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA. 2011;306(7):721-8.
  7. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-48.
  8. Haghighatafshar M, Ghaedian M, Etemadi Z, Entezarmahdi SM, Ghaedian T. Pilocarpine effect on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. Nucl Med Commun. 2018;39(5):430-4.
  9. Sisson TATAToRS, C J, Freitas J, McDougall IR, Dauer LT, Hurley JR, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-46.
  10. ICRP Publication 94: Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34(2):7-79.
  11. Scheffel RS, Zanella AB, Dora JM, Maia AL. Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid. 2016;26(11):1623-9.
  12. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, Togashi K, Itasaka S, Hiraoka M, Misaki T, Konishi J. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52(5):683-9.
  13. Li H, Zhang Yq, Wang C, Zhang X, Li X, Lin Ys. Delayed initial radioiodine therapy related to incomplete response in low‐to intermediate‐risk differentiated thyroid cancer. Clin Endocrinol. 2018;88(4):601-6.
  14. Seregni E, Lorenzoni A, Fugazzola L. Radioiodine therapy of thyroid cancer.  Clinical applications of nuclear medicine targeted therapy: Springer; 2018. p. 59-68.
  15. Avram AM, Rosculet N, Esfandiari NH, Gauger PG, Miller BS, Cohen M, Cohen M, Hughes DT. Differentiated Thyroid Cancer Outcomes After Surgery and Activity-adjusted 131i Theragnostics. Clin Nucl Med. 2019;44(1):11-20.
  16. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341-9.
  17. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer. 2011 Mar 3;18(2):R29-40.
  18. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart J-M, Travagli JP, Schlumberger M. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005 Oct;90(10):5723-9.
  19. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10 year foliow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70(3):511-8.
  20. Degroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414-24.
  21. Kim M, Han M, Jeon MJ, Kim WG, Kim IJ, Ryu JS, Kim WB, Shong YK, Kim TY, Kim BH. Impact of delayed radioiodine therapy in intermediate/high‐risk papillary thyroid carcinoma. Clin Endocrinol. 2019.
  22. Krajewska J, Jarzab M, Kukulska A, Czarniecka A, Roskosz J, Puch Z, Wygoda Z, Paliczka-Cieslik E, Kropinska A, Krol A, Handkiewicz-Junak D. Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma. Nucl Med Mol Imaging. 2019;53(5):320-7.